Volume 381, Issue 9880, Pages (May 2013)

Slides:

Advertisements

Similar presentations

Study of Tamoxifen and Raloxifene (STAR): Initial Findings from the NSABP P-2 Breast Cancer Prevention Study D.L. Wickerham, J.P. Costantino, V. Vogel,

Advertisements

1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer.

By: Erin Hutzell. Background: Breast Cancer Second leading cause of death due to cancer among women in in 3 women diagnosed with cancer is diagnosed.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta- analysis of the randomised trials The Lancet Volume 386, Issue 10001,

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Fever of unknown origin and cancer: a population-based study

Volume 370, Issue 9586, Pages (August 2007)

Ki67 in breast cancer: prognostic and predictive potential

Volume 384, Issue 9961, Pages (December 2014)

Volume 349, Issue 9057, Pages (April 1997)

Volume 387, Issue 10021, Pages (February 2016)

Volume 8, Issue 10, Pages (October 2009)

Volume 11, Issue 4, Pages (April 2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Volume 16, Issue 9, Pages (September 2015)

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

The benefits and harms of breast cancer screening

Ductal Carcinoma in Situ of the Breast

Neonatal vitamin A: time to move on?

Volume 378, Issue 9804, Pages (November 2011)

The Irish health-care system and austerity: sharing the pain

Volume 389, Issue 10076, Pages (April 2017)

Volume 9, Issue 12, Pages (December 2008)

Volume 9, Issue 5, Pages (May 2008)

Volume 373, Issue 9677, Pages (May 2009)

Aspirin in the prevention of cancer – Author's reply

Marc Carrier, MD, MSc, Alok A

Volume 375, Issue 9732, Pages (June 2010)

Volume 374, Issue 9707, Pages (December 2009)

Volume 9, Issue 9, Pages (September 2008)

Volume 373, Issue 9663, Pages (February 2009)

Volume 13, Issue 11, Pages (November 2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Volume 365, Issue 9466, Pages (April 2005)

Volume 366, Issue 9484, Pages (August 2005)

Volume 381, Issue 9869, Pages (March 2013)

Can plagues be predicted, prevented?

Incident diabetes in clinical trials of antihypertensive drugs

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study Sune F Nielsen, PhD, Prof Børge G Nordestgaard,

Volume 386, Issue 10001, Pages (October 2015)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised.

Volume 15, Issue 1, Pages (January 2014)

Post-imaging colorectal cancer or interval cancer rates after CT colonography: a systematic review and meta-analysis Anu E Obaro, FRCR, Andrew A Plumb,

Adrian Martineau The Lancet Respiratory Medicine

Volume 13, Issue 5, Pages (May 2012)

Volume 11, Issue 4, Pages (April 2010)

Volume 9, Issue 9, Pages (September 2008)

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Confessions of a journal junkie

Volume 373, Issue 9676, Pages (May 2009)

Volume 372, Issue 9647, Pages (October 2008)

Volume 393, Issue 10172, Pages (February 2019)

Volume 371, Issue 9627, Pages (May 2008)

Volume 387, Issue 10021, Pages (February 2016)

Volume 393, Issue 10172, Pages (February 2019)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Volume 9, Issue 4, Pages (April 2008)

Volume 383, Issue 9922, Pages (March 2014)

Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study Jeanette K Birnbaum, PhD,

Volume 15, Issue 13, Pages (December 2014)

Volume 375, Issue 9726, Pages (May 2010)

Prof GJB van Ommen, PhD, E Bakker, PhD, JT den Dunnen, PhD The Lancet

Volume 11, Issue 3, Pages (March 2010)

Volume 373, Issue 9672, Pages (April 2009)

Volume 383, Issue 9921, Pages (March 2014)

Volume 371, Issue 9618, Pages (March 2008)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 12, Issue 1, Pages (January 2011)

Effectiveness of strategies to improve health-care provider practices in low-income and middle-income countries: a systematic review Alexander K Rowe,

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Volume 381, Issue 9880, Pages 1827-1834 (May 2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data Prof Jack Cuzick, PhD, Ivana Sestak, PhD, Bernardo Bonanni, MD, Joseph P Costantino, DrPH, Steve Cummings, MD, Prof Andrea DeCensi, MD, Prof Mitch Dowsett, PhD, Prof John F Forbes, MD, Leslie Ford, MD, Prof Andrea Z LaCroix, PhD, John Mershon, MD, Bruce H Mitlak, MD, Prof Trevor Powles, MD, Prof Umberto Veronesi, MD, Prof Victor Vogel, MD, D Lawrence Wickerham, MD The Lancet Volume 381, Issue 9880, Pages 1827-1834 (May 2013) DOI: 10.1016/S0140-6736(13)60140-3 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Cumulative incidence for all breast cancer (including ductal carcinoma in situ) and all ER-positive invasive cancers in years 0–10 according to treatment allocation SERM=selective oestrogen receptor modulator. ER=oestrogen receptor. The Lancet 2013 381, 1827-1834DOI: (10.1016/S0140-6736(13)60140-3) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Annual hazard rate for all breast cancers (including ductal carcinoma in situ) and invasive ER-positive breast cancer in years 0–10 with fixed-effects models23 ER=oestrogen receptor. SERM=selective oestrogen receptor modulator. The Lancet 2013 381, 1827-1834DOI: (10.1016/S0140-6736(13)60140-3) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 All breast cancers, invasive breast cancer, and DCIS in years 0–10 ER=oestrogen receptor. DCIS=ductal carcinoma in situ. *Adjusted by overall tamoxifen effect to give raloxifene versus placebo comparisons. † STAR data not included in comparisons. ‡Data for ER-invasive cancer are pooled. The Lancet 2013 381, 1827-1834DOI: (10.1016/S0140-6736(13)60140-3) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 Forest plots for adverse events (A) Endometrial cancer, other cancer, venous thromboembolic events, and cardiac or stroke events. (B) All fractures, vertebral fractures and non-vertebral fractures. *Adjusted by overall tamoxifen effect to give raloxifene versus placebo comparisons. † STAR data not included in comparisons. ‡Data are pooled. The Lancet 2013 381, 1827-1834DOI: (10.1016/S0140-6736(13)60140-3) Copyright © 2013 Elsevier Ltd Terms and Conditions